title: Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.
abstract: Natural killer (NK) cells are important innate effector cells which can irradicate tumor cells through specific interactions between activating receptors on NK cells and their cognate ligands on cancer cells. Recently, it has been known that induction of activating NKG2D ligands including MHC class I chain-related (MIC) and UL16-binding protein (ULBP) families on tumor cells by various stresses makes them more susceptible to NK cell-mediated cytotoxicity. Therefore, it was investigated whether sublethal dose of hematoporphyrin-based photodynamic therapy (PDT) could up-regulate NKG2D ligands on tumor cells and increase the susceptibility of cancer cells against NK cells. Treatment with sublethal dose of hematoporphyrin-based PDT increased mRNA transcription and surface expression of ULBP1 and ULBP2 genes in SNU-1 human gastric tumor cell line and MICA/B, ULBP1, ULBP2 and ULBP3 genes in SW-900 human lung cancer cell line. These results were followed by increased susceptibility of cancer cells to NK cell-mediated cytotoxicity after sublethal PDT, which was abolished by addition of a blocking NKG2D mAb. Therefore, it could be suggested that the effect of hematoporphyrin-based PDT might be mediated in part by the increased susceptibility to NK cells via induction of NKG2D ligands on tumor cells, which survived after treatment with PDT.
authors.affiliation: Department of Biochemistry, Pusan National University School of Medicine, Yangsan 626-870, South Korea.
authors.forename: Min-Ju
authors.initials: MJ
authors.lastname: Park
authors.forename: Jae-Ho
authors.initials: JH
authors.lastname: Bae
authors.forename: Joo Seop
authors.initials: JS
authors.lastname: Chung
authors.forename: Sun-Hee
authors.initials: SH
authors.lastname: Kim
authors.forename: Chi-Dug
authors.initials: CD
authors.lastname: Kang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology; D045744:Cell Line, Tumor / Q000276:immunology / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D015972:Gene Expression Regulation, Neoplastic; D006415:Hematoporphyrins / Q000378:metabolism; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D008024:Ligands; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology; D055655:NK Cell Lectin-Like Receptor Subfamily K / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D010778:Photochemotherapy; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000276:immunology; D015854:Up-Regulation
chemical_list: D006415:Hematoporphyrins; C527085:KLRK1 protein, human; D008024:Ligands; D055655:NK Cell Lectin-Like Receptor Subfamily K